Full Press Release Details
IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1 2 Tissue Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations.
IDYA
IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1 2 Tissue Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations
Key Takeaway: IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1 2 Tissue Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma